Diotallevi Federico, Matacchione Giulia, d'Agostino Giovanni Marco, Gioacchini Helena, Campanati Anna, Sabbatinelli Jacopo, Olivieri Fabiola, Offidani Annamaria
Dermatological Clinic, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy.
Dermatol Ther (Heidelb). 2023 Jun;13(6):1377-1387. doi: 10.1007/s13555-023-00931-1. Epub 2023 May 17.
The key role of microRNAs (miRNAs) in the pathogenesis of psoriasis has been extensively discussed in the literature. Increasing evidence suggests that the analysis of miRNA levels may constitute an innovative approach for exploring the clinical efficacy of anti-inflammatory therapies in patients with psoriasis. However, so far there have been no published studies evaluating the effects of modulating circulating miRNAs and the efficacy of anti-interleukin-23 (anti-IL-23) therapy. The main objective of the present was to evaluate the diagnostic/prognostic relevance of the levels of five circulating candidate miRNAs (miR-21, miR-146a, miR-155, miR-210, miR-378) in psoriatic patients treated with the anti-IL-23 drug risankizumab.
A total of eight psoriatic participants were recruited consecutively from January 2021 to July 2021 at the Dermatology Clinic of Università Politecnica delle Marche (UNIVPM) "Ospedali Riuniti" of Marche. Data on anamnestic, clinical and miRNA evaluations before the initiation of risankizumab therapy and after 1 year (January 2021-July 2022) of risankizumab therapy were available for all patients.
A significant reduction in the signs and symptoms in patients treated with risankizumab was observed after 1 year of treatment, suggesting that the drug is effective for treating psoriasis in a context of real-life clinical evaluation. Plasma levels of the two prototypical inflammamiRs, miR-146a and miR-155, were significantly reduced after 1 year of risankizumab therapy. Also, in patients before treatment, a significant positive correlation was found between circulating levels of miR-210 and miR-378 and disease severity scores.
Our results reinforce the notion that specific circulating miRNAs could have clinical relevance as diagnostic/prognostic biomarkers of psoriatic disease and suggest the potential relevance of these miRNAs as biomarkers of treatment response.
微小RNA（miRNA）在银屑病发病机制中的关键作用已在文献中得到广泛讨论。越来越多的证据表明，分析miRNA水平可能构成一种探索抗炎疗法对银屑病患者临床疗效的创新方法。然而，迄今为止，尚无已发表的研究评估调节循环miRNA的效果以及抗白细胞介素-23（抗IL-23）疗法的疗效。本研究的主要目的是评估在接受抗IL-23药物司库奇尤单抗治疗的银屑病患者中，五种循环候选miRNA（miR-21、miR-146a、miR-155、miR-210、miR-378）水平的诊断/预后相关性。
2021年1月至2021年7月，在马尔凯理工大学“联合医院”皮肤科诊所连续招募了8名银屑病患者。所有患者均有司库奇尤单抗治疗开始前以及司库奇尤单抗治疗1年（2021年1月至2022年7月）后的病史、临床和miRNA评估数据。
治疗1年后，观察到接受司库奇尤单抗治疗的患者的体征和症状显著减轻，这表明在现实生活临床评估中，该药物对治疗银屑病有效。司库奇尤单抗治疗1年后，两种典型炎症miRNA（miR-146a和miR-155）的血浆水平显著降低。此外，在治疗前的患者中，发现miR-210和miR-378的循环水平与疾病严重程度评分之间存在显著正相关。
我们的结果强化了这样一种观念，即特定的循环miRNA可能作为银屑病疾病的诊断/预后生物标志物具有临床相关性，并表明这些miRNA作为治疗反应生物标志物的潜在相关性。
